DaVita Inc. (NYSE:DVA) Given Consensus Rating of "Hold" by Brokerages

DaVita Inc. (NYSE:DVA - Get Free Report) has earned a consensus rating of "Hold" from the six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $164.50.

DVA has been the topic of a number of recent research reports. Truist Financial lowered their price objective on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research note on Monday, May 19th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th.

DaVita Price Performance

DaVita stock opened at $136.66 on Monday. The stock's fifty day moving average price is $139.84 and its two-hundred day moving average price is $150.02. DaVita has a one year low of $131.76 and a one year high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. The firm has a market cap of $10.32 billion, a PE ratio of 13.54, a price-to-earnings-growth ratio of 0.94 and a beta of 1.11.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The firm had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. During the same quarter last year, the company earned $2.26 EPS. The company's revenue was up 5.0% on a year-over-year basis. As a group, research analysts expect that DaVita will post 10.76 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

Several hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. increased its stake in shares of DaVita by 3.4% in the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company's stock valued at $251,322,000 after purchasing an additional 53,402 shares during the last quarter. Northern Trust Corp grew its position in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company's stock worth $136,240,000 after acquiring an additional 149,858 shares during the last quarter. Gates Capital Management Inc. grew its position in DaVita by 0.7% during the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company's stock worth $110,476,000 after acquiring an additional 4,698 shares during the last quarter. Amundi grew its position in DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company's stock worth $79,584,000 after acquiring an additional 71,304 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in DaVita by 14.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after acquiring an additional 57,386 shares during the last quarter. Institutional investors own 90.12% of the company's stock.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.